Humanin vs PEG-MGF
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Side-by-Side Comparison
| Aspect | Humanin | PEG-MGF |
|---|---|---|
| Mechanism | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. |
| Typical Dosage | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. |
| Administration | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. |
| Side Effects | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. |
| Best For |